Division of Colon and Rectal Surgery, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.
Division of Hepatobiliary and Pancreatic Surgery, The Ottawa Hospital, Ottawa, ON, Canada.
J Gastrointest Surg. 2019 Jun;23(6):1188-1197. doi: 10.1007/s11605-019-04186-0. Epub 2019 Mar 18.
The impact of immunosuppressants on postoperative complications following colon resections for Crohn's disease remains controversial. This study aimed to compare postoperative outcomes between immunosuppressed and immunocompetent patients with Crohn's disease undergoing elective colon resection.
Analysis of 30-day outcomes using a cohort from the American College of Surgeons National Surgical Quality Improvement Program colectomy-specific database was performed. The database is populated by trained clinical reviewers who collect 30-day postoperative outcomes for patients treated at participating North-American institutions. Adult patients who underwent an elective colectomy between 2011 and 2015 were included. Immunosuppression for Crohn's disease was predefined as use of regular corticosteroids or immunosuppressants within 30 days of the operation. Patients who received chemotherapy within 90 days of surgery, and patients who had disseminated cancer, preoperative shock, or emergency surgery were excluded. Primary outcome was infectious complications.
Three thousand eight hundred sixty patients with Crohn's disease required elective colon resection and met the inclusion criteria. Of these, 2483 were immunosuppressed and 1377 were immunocompetent. On multivariate analysis, the odds of infectious complications [OR 1.25; 95% CI (1.033-1.523)], overall surgical site infection [1.40; (1.128-1.742)], organ space surgical site infection [1.47; (1.094-1.984)], and anastomotic leak [1.51; (1.018-2.250)] were significantly higher for immunosuppressed compared to immunocompetent patients with Crohn's disease.
Patients with Crohn's disease who were on immunosuppressant medications within 30 days of elective colectomy had significantly increased rates of infectious complications, overall surgical site infection, organ space surgical site infection, and anastomotic leak compared to patients who were not on immunosuppressive agents.
免疫抑制剂对克罗恩病结肠切除术术后并发症的影响仍存在争议。本研究旨在比较接受择期结肠切除术的克罗恩病免疫抑制和免疫功能正常患者的术后结局。
使用美国外科医师学院国家手术质量改进计划结肠切除术特定数据库中的队列分析 30 天结果。该数据库由经过培训的临床审查员填充,他们为参与北美的机构治疗的患者收集 30 天术后结果。纳入 2011 年至 2015 年间接受择期结肠切除术的成年患者。克罗恩病的免疫抑制定义为在手术前 30 天内使用常规皮质类固醇或免疫抑制剂。排除在手术前 90 天内接受化疗、患有转移性癌症、术前休克或急诊手术的患者。主要结局是感染性并发症。
3860 例克罗恩病患者需要择期结肠切除术,符合纳入标准。其中 2483 例为免疫抑制患者,1377 例为免疫功能正常患者。多变量分析显示,感染性并发症的可能性[比值比 1.25;95%置信区间 (1.033-1.523)]、总体手术部位感染[1.40;(1.128-1.742)]、器官间隙手术部位感染[1.47;(1.094-1.984)]和吻合口漏[1.51;(1.018-2.250)]的可能性在免疫抑制患者中明显高于免疫功能正常患者。
在择期结肠切除术前 30 天内接受免疫抑制剂治疗的克罗恩病患者与未接受免疫抑制剂治疗的患者相比,感染性并发症、总体手术部位感染、器官间隙手术部位感染和吻合口漏的发生率明显增加。